Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
This marks the first partnership between Pfizer and Cipla in India
Subscribe To Our Newsletter & Stay Updated
